ReviewJournal of immunology (Baltimore, Md. : 1950)2020
Antibody Responses to SARS-CoV-2: Let's Stick to Known Knowns.
Review in Journal of immunology (Baltimore, Md. : 1950), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 87 citations in OpenAlex.
- Relationship of various COVID-19 antibody titer with individual characteristics and prediction of future epidemic trend in Xiamen City, China.Journal of thoracic disease · 2024Article
- Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy.Clinical reviews in allergy & immunology · 2023Review
- Diagnostic performance of four lateral flow immunoassays for COVID-19 antibodies in Peruvian population.PLOS global public health · 2023Article
- Clinical characteristics and severity of beta and delta variants of SARS-CoV-2 and the effect of vaccine on delta variants.Heliyon · 2022Article
- Vaccine-Induced T-Cell and Antibody Responses at 12 Months after Full Vaccination Differ with Respect to Omicron Recognition.Vaccines · 2022Article
- Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi population.Scientific reports · 2022Article
- Antibodies against SARS-CoV-2 after natural infection in healthcare workers and clinical characteristics as putative antibody production prediction.Journal of clinical virology plus · 2022Article
- Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study.EClinicalMedicine · 2022Article
- Distinct Cellular Immune Responses to SARS-CoV-2 in Pregnant Women.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- COVID-19 Vaccines: Current and Future Perspectives.Vaccines · 2022Review
- Continued Virus-Specific Antibody-Secreting Cell Production, Avidity Maturation and B Cell Evolution in Patients Hospitalized with COVID-19.Viral immunology · 2022Article
- Analysis of long-term antibody response in COVID-19 patients by symptoms grade, gender, age, BMI, and medication.Journal of medical virology · 2022Article
- Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers.Vaccines · 2022Article
- Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines.Journal of microbiology (Seoul, Korea) · 2022Review
- Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG.iScience · 2022Article
- A review of hypersensitivity methods to detect immune responses to SARS-CoV-2.Methods in microbiology · 2022Article
- Immunity to SARS-CoV-2 induced by infection or vaccination.Journal of internal medicine · 2022Review
- Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic.International journal of biological sciences · 2022Review
- The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection.Frontiers in immunology · 2022Review
- Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines.Infection and drug resistance · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
The scale of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has thrust immunology into the public spotlight in unprecedented ways. In this article, which is part opinion piece and part review, we argue that the normal cadence by which we discuss science with our colleagues failed to properly convey likelihoods of the immune response to SARS-CoV-2 to the public and the media. As a result, biologically implausible outcomes were given equal weight as the principles set by decades of viral immunology. Unsurprisingly, questionable results and alarmist news media articles have filled the void. We suggest an emphasis on setting expectations based on prior findings while avoiding the overused approach of assuming nothing. After reviewing Ab-mediated immunity after coronavirus and other acute viral infections, we posit that, with few exceptions, the development of protective humoral immunity of more than a year is the norm. Immunity to SARS-CoV-2 is likely to follow the same pattern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.